Albany, NY -- (SBWIRE) -- 11/29/2019 -- Chronic Inflammatory Demyelinating Polyneuropathy Market Insights, Epidemiology and Market Forecast-2028

1. Chronic Inflammatory Demyelinating Polyneuropathy prevalent cases were 46,351 in 2016 in the 7MM.
2. In 2016, there were around 6,477 Chronic Inflammatory Demyelinating Polyneuropathy cases in the USA.
3. There were 610 total Chronic Inflammatory Demyelinating Polyneuropathy incident cases in Japan.

(Albany, US) DelveInsight launched a new report on Chronic Inflammatory Demyelinating Polyneuropathy Market Insights, Epidemiology and Market Forecast-2028

Key benefits

1. Chronic Inflammatory Demyelinating Polyneuropathy market report covers a descriptive overview and comprehensive insight of the Chronic Inflammatory Demyelinating Polyneuropathy epidemiology and Chronic Inflammatory Demyelinating Polyneuropathy market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Chronic Inflammatory Demyelinating Polyneuropathy market report provides insights on the current and emerging therapies.
3. Chronic Inflammatory Demyelinating Polyneuropathy market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Chronic Inflammatory Demyelinating Polyneuropathy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Chronic Inflammatory Demyelinating Polyneuropathy market.

Request for sample pages

"Among the five major European Markets (EU5), the total number of CIDP prevalent cases was 13,539 cases in 2016."

The mainstay of CIDP treatment consists of corticosteroids, IVIG (intravenous immunoglobulin) and plasma exchange (Plex) or some combination of these agents. These are the first-line therapies for CIDP. However, these therapies cause significant potential side-effects that can limit their use. Though corticosteroids are generally inexpensive, both IVIG and PLEX are expensive, labour intensive and lengthy treatments which again a downside on the CIDP treatment part. All the above treatments are aimed at stopping the inflammatory response to prevent further demyelination and secondary axonal injury.

Other treatments may be considered in patients with refractory disease, but reliable, supportive data for their efficacy is generally lacking. Additionally, many of these second- and third-line agents pose the risk of rare but serious side effects. There are many drugs that are used in refractory cases such as Cyclophosphamide; cyclosporine A has been recommended for severe refractory cases. The immunosuppressive drugs such as azathioprine and methotrexate, neither of which has clinical benefit in case of CIDP. However, these agents may be utilised with corticosteroids to decrease IVIg or PE requirement or when they are not effective, and their use is widespread. Another drug which is considered is Rituximab which is beneficial in a subset of treatment-resistant patients with antibodies against node of Ranvier proteins CNTN1 and NF155.
CIDP is one of the most lucrative markets for the use of IVIG due to fewer side effects associated with its use. In 2016, the USA was the largest Chronic Inflammatory Demyelinating Polyneuropathy market due to the maximum incidence of immunodeficiency diseases, including CIDP, and high healthcare expenditure. Europe is the second-fastest-growing region after the US.

The launch of the emerging therapies is expected to significantly impact Chronic Inflammatory Demyelinating Polyneuropathy treatment scenario in the upcoming years:-
Drugs covered
1. HYQVIA
2. NewGam
And many others

The key players in Chronic Inflammatory Demyelinating Polyneuropathy market are:
1. Baxalta
2. Octapharma
And many others

Table of contents

1. Report Introduction
2. Chronic Inflammatory Demyelinating Polyneuropathy Market Overview at a Glance
3. CIDP Disease Background and Overview
4. Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology and Patient Population
5. Chronic Inflammatory Demyelinating Polyneuropathy Country- Wise Epidemiology
5.1. United States
5.2. EU-5
5.2.1. Germany
5.2.2. France
5.2.3. Italy
5.2.4. Spain
5.2.5. United Kingdom
5.3. Japan
6. Unmet Medical Needs in CIDP
7. Chronic Inflammatory Demyelinating Polyneuropathy Treatment & Medical Practices
8. Chronic Inflammatory Demyelinating Polyneuropathy Marketed Products
8.1. Gammaked: Kedrion Biopharma
8.2. Gamunex-C: Grifols
9. Chronic Inflammatory Demyelinating Polyneuropathy Emerging Therapies
9.1. Key Cross Competition
9.2. HYQVIA: Baxalta
9.3. NewGam: Octapharma
10. 7MM Chronic Inflammatory Demyelinating Polyneuropathy Country-Wise Market Analysis
10.1. United States
10.2. Germany
10.3. France
10.4. United Kingdom
10.5. Spain
10.6. Italy
10.7. Japan
11. Market Drivers
12. Market Barriers
13. Apendix
14. Chronic Inflammatory Demyelinating Polyneuropathy Report Methodology
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight